HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Durbin’s DoD Supplement Proposal Could Be ‘Back Door’ To Pre-market Approval Rule

This article was originally published in The Tan Sheet

Executive Summary

The Illinois senator proposes an amendment to the National Defense Authorization Act that would require third-party verification for supplements sold at any commissary or other retail store operating on a DoD installation.

You may also be interested in...



Military Report Slams DMAA While GNC Claims Victory

A Department of Defense safety review panel does not find a conclusive causal association between DMAA and adverse events, including four service members’ deaths, a conclusion that “delighted” retailer GNC. But DoD’s ban on sales of DMAA products in military exchanges and concessions remains in place.

In Brief: Acetaminophen Warnings, OTC HSA Bill, Durbin’s Supplement Reg Bill

FDA adds acetaminophen warnings; CHPA suggests 4-aminophenol standard; OTC HSA bill in House; supplement registration bill reintroduced; FSMA user fees still on hold; more scrutiny of energy drinks; and Public Citizen pans OTC Oxytrol.

FDA Needs To Track Actions Built On Supplement AERs – GAO Report

A GAO report says FDA “may be able to expand” its use of supplement adverse event reports if it can track its use of the data to support actions it takes to protect consumers. The report makes five key recommendations for the agency to improve its approach to AERs.

Topics

UsernamePublicRestriction

Register

RS123754

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel